Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

HOTH
Hoth Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jun 30, 2025 3:59:30 PM EDT
1.18USD+3.982%(+0.05)411,918
1.16Bid   1.18Ask   0.02Spread
Pre-market
Jun 30, 2025 9:22:30 AM EDT
1.15USD+1.761%(+0.02)15,714
After-hours
Jun 30, 2025 4:34:30 PM EDT
1.18USD+0.426%(+0.01)7,173
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
08:19AM EST  Hoth Appoints John Cirrito And Carla Yuede To Scientific Advisory Board   RTTNews
08:17AM EST  Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board   PR Newswire
Jan 4, 2022
04:21PM EST  EXCLUSIVE: Hoth Therapeutics Speaks To Benzinga As Stock Spikes Over 90% On Newly Released Proof-Of-Concept Data   Benzinga
01:46PM EST  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Says Co Has Some 'Big Data' Coming Out In The Next Couple Of Months From The Co's Clinical Trials   Benzinga
01:37PM EST  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Says Co Is Looking Into Fundraising In The Near Future   Benzinga
01:34PM EST  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Says Co's Next Step Is To Look At A Longer Study 'Cognitive Behavioral Effects'   Benzinga
01:30PM EST  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. Now Interviewing On Benzinga's Live YouTube TV   Benzinga
10:54AM EST  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns, Ph.D. To Appear On Benzinga's Live YouTube TV At 1:30 p.m. ET On Tuesday   Benzinga
08:35AM EST  Hoth Therapeutics, Inc. (HOTH) reported proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. The company said a significant decline in A was seen in the Alzheimer's disease mouse model after acute treatment with HT-ALZ.   RTTNews
08:09AM EST  Hoth Reports HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid In Alzheimer's Disease; Stock Up   RTTNews
08:05AM EST  Hoth Therapeutics Highlights Proof-Of-Concept Data Generated Using An Alzheimer's Disease Mouse Model Supporting Therapeutic Potential Of Co.'s HT-ALZ   Benzinga
08:03AM EST  Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce   PR Newswire
Dec 21, 2021
08:00AM EST  Hoth Announces Submission Of Orphan Drug Designation Request For HT-KIT To Treat Mastocytosis   RTTNews
07:59AM EST  Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for   PR Newswire
07:59AM EST  Hoth Therapeutics Announces Submission Of Orphan Drug Designation Request For HT-KIT To Treat Mastocytosis   Benzinga
Dec 8, 2021
08:02AM EST  Hoth Therapeutics Licenses Lupus Therapeutic Back to Zyl Therapeutics   PR Newswire
07:30AM EST  EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zyl   Benzinga
07:30AM EST  EXCLUSIVE: Hoth Therapeutic Says 'Will Receive Shares In Zyl And Potential Future Sales Royalties'   Benzinga
07:30AM EST  EXCLUSIVE: Hoth Therapeutics Announces License Deal With Zyl Therapeutics To License Its Novel Cannabinoid Therapeutic, HT-005 For Lupus Patients, No Specific Terms Disclosed   Benzinga
07:30AM EST  EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zyl   Benzinga
Nov 30, 2021
04:44PM EST  EXCLSUIVE: Hoth Therapeutics Says Enrollment And Dosing Has Begun For Second Cohort In First In-Human Clinical Trial Investigating Topical BioLexa For The Treatment Of Mild-To-Moderate Atopic Dermatitis   Benzinga
04:44PM EST  EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa   Benzinga
04:44PM EST  EXCLSUIVE: Hoth Therapeutics Says Enrollment And Dosing Has Begun For Second Cohort In First In-Human Clinical Trial Investigating Topical BioLexa For The Treatment Of Mild-To-Moderate Atomic Dermatitis   Benzinga
08:13AM EST  Hoth Says Enrollment And Dosing In Second Cohort In Phase 1b Human Trial For Atopic Dermatitis Under Way   RTTNews
08:01AM EST  Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human   PR Newswire
Nov 16, 2021
08:44AM EST  Hoth Inks Research Agreement With North Carolina State University For Study of Preclinical Candidate To Treat Mast Cell Cancers   Benzinga
08:33AM EST  Hoth Therapeutics Announces Agreement To Further Develop Novel MRNA Cancer Therapeutic HT-KIT   RTTNews
08:31AM EST  Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop   PR Newswire
08:01AM EST  EXCLUSIVE: Hoth Says Research 'will focus on characterizing the HT-KIT dose and dosing frequency for treatment of aggressive mastocytosis and mast cell neoplasms using humanized tumor mouse models'   Benzinga
08:01AM EST  EXCLUSIVE: Hoth Therapeutics Announced It Has Signed A Sponsored Research Agreement With North Carolina State University To Support The Continued Research And Development Of HT-KIT   Benzinga
Nov 8, 2021
08:43AM EST  Hoth Signs API And Drug Product Contracts With WuXi STA To Advance Manufacturing Of HT-KIT Cancer Therapeutic   RTTNews
08:40AM EST  Hoth Therapeutics Reports 2 Contracts With WuXi AppTec's STA Pharma For Process Development, Manufacturing Of Active Pharmaceutical Ingredient, Formulation Of Drug Product For Continued Development, Commercialization Of HT-KIT Therapeutic   Benzinga
08:38AM EST  Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance   PR Newswire
Oct 19, 2021
12:48PM EDT  Hoth Therapeutics Extends Partnership Agreement With REPROCELL; Terms Not Disclosed   Benzinga
12:48PM EDT  Hoth Therapeutics Extends Partnership Agreement with REPROCELL   PR Newswire
Oct 12, 2021
10:04AM EDT  Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans   Benzinga
10:03AM EDT  Hoth Therapeutics Gets Approval To Commence Cohort 2 In Trial Of BioLexa For Treatment Of Atopic Dermatitis Patients   RTTNews
10:02AM EDT  Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of   PR Newswire
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
09:27AM EDT  Alkido Pharma Trading 30% Below Cash Value Despite Positive Indications   Benzinga
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Sep 30, 2021
03:13PM EDT  From BZ's Small Cap Healthcare Conference: Hoth Therapeutics CEO Robb Knie Discusses HT-001, Says EFGR Inhibitor Skin Toxicity Market Predicted To Grow From $52M In 2018 To $391M By End Of 2030   Benzinga
03:05PM EDT  From BZ's Small Cap Healthcare Conference: Hoth Therapeutics CEO Robb Knie Begins Speaking   Benzinga
Sep 22, 2021
07:05AM EDT  Hoth Therapeutics, Inc. To Present At The Benzinga Healthcare Small Cap Conference   Benzinga
Sep 21, 2021
10:07AM EDT  Hoth Submits To Ethics Committee For Approval To Initiate Patient Cohort 2 In BioLexa Clinical Trial   RTTNews
10:06AM EDT  Hoth Therapeutics Submits To Ethics Committee For Approval To Initiate Patient Cohort 2 In BioLexa Clinical Trial   Benzinga
10:05AM EDT  Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient   PR Newswire
Sep 8, 2021
12:48PM EDT  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns Says Co's Clinical Trial HT003 Is Coming Up Shortly, Says It Might Be A 'Breakthrough'   Benzinga
12:35PM EDT  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns Now Interviewing On Benzinga's Power Hour Show   Benzinga
11:38AM EDT  EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns To Appear On Benzinga's Power Hour Show At 12:30 p.m. EDT   Benzinga
08:11AM EDT  Hoth Therapeutics Announces Positive Phase 1b Results From First Cohort Of Patient Trial Of BioLexa   RTTNews
08:10AM EDT  EXCLUSIVE: Hoth Reports Safety Data From Early-Stage Study Of BioLexa Platform In Eczema   Benzinga
08:03AM EDT  Hoth Therapeutics Announces Positive Phase 1b Results for Completed First   PR Newswire
07:56AM EDT  EXCLUSIVE: Hoth Reports Positive Safety Data From Early-Stage Study Of BioLexa Platform In Eczema   Benzinga
07:55AM EDT  EXCLUSIVE: Hoth Therapeutics Announces Results In Cohort 1 Of Human Clinical Trial Of BioLexa In Eczema; Says No Serious Adverse Events And No Drug-Related Treatment-Emergent Adverse Events Observed   Benzinga
Aug 26, 2021
08:28AM EDT  Hoth 8-K Shows Co. Disclosed Research Sponsored By Co. On Variants Of Sars-CoV-2 Virus Published In 'Microbiology Spectrum'   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 11, 2021
09:08AM EDT  Hoth Therapeutics Highlights North Carolina State University Findings Of HT-KIT   Benzinga
09:03AM EDT  Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers   PR Newswire
Aug 10, 2021
05:13PM EDT  Paper Out Of NC State University Earlier, Published In Molecular Therapy ''Frameshifting' Therapy for Mast Cell Cancers Reduces Size, Spread' Highlights Hoth Therapeutics Technology   Benzinga
Aug 2, 2021
11:11AM EDT  Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate   Benzinga
08:17AM EDT  Hoth Therapeutics Initiates Preclinical Study Of HT-ALZ For Alzheimer's Disease   RTTNews
08:16AM EDT  Hoth Therapeutics Reports Initiation Of Preclinical Study Of HT-ALZ For Alzheimer's Disease   Benzinga
08:15AM EDT  Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease   PR Newswire
Jul 13, 2021
10:13AM EDT  Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model   Benzinga
08:19AM EDT  Hoth Therapeutics: HT-003 Group Of Assets Yields Positive Results In An In Vivo Acne Therapeutic Model   RTTNews
08:16AM EDT  Hoth Therapeutics Announces Confirmatory Results From In Vivo Model Of HT-003 As Potential Treatment Against Acne; Model Showed HT-003 'reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology'   Benzinga
08:15AM EDT  Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of   PR Newswire
Jun 28, 2021
08:12AM EDT  Hoth Therapeutics Announces Positive Results From AD001 Cohort 1 Of Phase 1b Trial Of BioLexa For Atopic Dermatitis   RTTNews
08:08AM EDT  Hoth Therapeutics Announces Safety Results From AD001 Cohort 1 Of Phase 1b Clinical Trial Of BioLexa For Treatment Of Atopic Dermatitis; Interim Data Indicates BioLexa Was Well Tolerated With No Serious Adverse Effects   Benzinga
08:02AM EDT  Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of   PR Newswire
Jun 18, 2021
06:14AM EDT  Hoth Therapeutics 8-K Shows Co. Entered Non-Exclusive Commercial Evaluation License Deal With US Army Medical Research, Development Command For 12-Month Extension   Benzinga
Jun 7, 2021
02:32PM EDT  Hoth Therapeutics Announces Sponsored Research Agreement with Washington   PR Newswire
Jun 3, 2021
12:32PM EDT  Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program   Benzinga
08:10AM EDT  Hoth Therapeutics Shares Positive Preclinical Results Of Novel HT-KIT Therapeutic   RTTNews
08:06AM EDT  Hoth Therapeutics To Present Data On Preclinical Results For Its HT-KIT For mRNA Frame-Shifting On Jun. 3 at 1 p.m. EDT   Benzinga
08:03AM EDT  Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT   PR Newswire
Jun 1, 2021
08:06AM EDT  Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's   PR Newswire
May 24, 2021
08:02AM EDT  Hoth Therapeutics Announces Participation at the American Society of Clinical   PR Newswire
May 18, 2021
10:44AM EDT  HOTH Therapeutics (NASDAQ: HOTH): Developing Life-Changing Drugs for Rare Cancers and Diseases   Benzinga
May 13, 2021
08:30AM EDT  Hoth Therapeutics Provides Shareholder Update On Endocannabinoid Therapeutic For Cutaneous Lupus Erythematosus   Benzinga
08:28AM EDT  Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid   PR Newswire
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
08:18AM EDT  Hoth Therapeutics In 8K Filing Says On May 3 Received Notice Of Allowance From U.S. Patent And Trademark Office With Respect To Patent Titled 'Nano Hole Array Based Plasmonic Gas Sensor with Various Coating and Temperature Control'   Benzinga
May 5, 2021
09:28AM EDT  Hoth Therapeutics, Virginia Commonwealth University Expand Research Agreement For COVID-19 Therapeutic   RTTNews
09:27AM EDT  Hoth Therapeutics and Virginia Commonwealth University Expand Research   PR Newswire
09:27AM EDT  Hoth Therapeutics Says Co, Virginia Commonwealth University Expand Research Agreement For COVID-19 Therapeutic   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 3, 2021
09:14AM EDT  Hoth Therapeutics Reports Intent To Pursue Development Of Its HT-KIT mRNA Frame Shifting Therapeutic For Multiple Orphan Diseases   Benzinga
09:13AM EDT  Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan   PR Newswire
Apr 22, 2021
09:14AM EDT  Hoth Says Its First In Human Clinical Trial For Treatment Of Atopic Dermatitis With BioLexa Underway   RTTNews
09:04AM EDT  Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic   PR Newswire
09:04AM EDT  Hoth Therapeutics Says First In Human Clinical Trial For Treatment Of Atopic Dermatitis With BioLexa Is Underway   Benzinga
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 20, 2021
02:07PM EDT  Hoth Therapeutics' mRNA Frame Shifting Therapeutic Inhibits Tumor Growth, Animal Study Shows   Benzinga
09:15AM EDT  Hoth Therapeutics Says Its mRNA Frame Shifting Therapeutic Exhibited 'highly positive' Results In Humanized Mast Cell Neoplasm Models   Benzinga
09:12AM EDT  Hoth Announces MRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth In Mast Cell-Derived Cancers   RTTNews
09:06AM EDT  Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly   PR Newswire
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 15, 2021
08:37AM EDT  Hoth Received Confirmation Of Filing Of Assignment Of Ownership Of Provisional Patent Application For Use Of One Of Co.'s Therapeutic For Alzheimer's Disease   Benzinga
08:36AM EDT  Hoth Received Confirmation Of Filing Of International Patent Applications In China, Japan For Use Of A Therapeutic To Treat Asthma, Anaphylactic Shock   Benzinga
Apr 13, 2021
08:07AM EDT  Hoth Therapeutics Partner Voltron Therapeutics Highlights Apr. 8 COVID-19 And Pandemic Preparedness Presentation To Multiple US Agencies   Benzinga
08:00AM EDT  Voltron Therapeutics, Inc.today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on Thursday April 8th. This follows dozens of recent one-on-one briefings with Congressional staffers.   GlobeNewswire Inc
Apr 12, 2021
09:20AM EDT  Hoth Therapeutics Completes HT-001 Formulation Development   Benzinga
09:15AM EDT  Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer   PR Newswire
Apr 6, 2021
09:20AM EDT  Hoth Engages Clinical Trials As Contract Research Organization For Phase 2a HT-001 Trial For Cancer Patients   RTTNews
09:16AM EDT  Hoth Therapeutics Reports Has Engaged Worldwide Clinical Trials For Its Upcoming Phase 2a Dose Ranging Trial Of HT-001 For Treatment Of Cutaneous Toxicities Associated With EGFR Inhibitor Therapy For Cancer Patients   Benzinga
09:15AM EDT  Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research   PR Newswire
Apr 5, 2021
08:20AM EDT  Hoth Announces Notice Of Allowance For New Patent Application Related To Method For Inhibiting Formation Of Biofilm   RTTNews
08:04AM EDT  Hoth Therapeutics Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm   Benzinga
08:02AM EDT  Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent   PR Newswire
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 24, 2021
10:26AM EDT  Hoth Therapeutics' Partner Voltron Therapeutics Reports Encouraging Preclinical Data From COVID-19 Vaccine Candidate   Benzinga
08:29AM EDT  Voltron Therapeutics Reports Positive Data From Animal Testing Of Its HaloVax SAV Against COVID-19   RTTNews
08:09AM EDT  Voltron Therapeutics, Inc. Announces Data From Animal Testing Of HaloVax Self-Assembling Vaccine For COVID-19, Which Is Being Developed In Conjunction With Hoth Therapeutics   Benzinga
08:00AM EDT  Voltron Therapeutics, Inc. Announces Positive Data from Animal   GlobeNewswire Inc
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
12:05PM EDT  Mid-Day Market Update: Crude Oil Down 4.5%; Hoth Therapeutics Shares Spike Higher   Benzinga
08:36AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Mar. 23, 2021: GME, HOTH, U, CLPS, SLGG   Benzinga
08:27AM EDT  Hoth Therapeutics Stock Rallies As Lead Peptide Candidate Shows Encouraging Preclinical Antiviral Activity Against COVID-19   Benzinga
08:21AM EDT  Hoth: Extremely Positive In Vitro Data Supports HT-002's   RTTNews
08:10AM EDT  Hoth Therapeutics Announces Positive Preclinical Results For Novel COVID-19 Therapeutic; Stock Surges   RTTNews
08:03AM EDT  Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19   PR Newswire
08:02AM EDT  Hoth Therapeutics Reports In Vitro Data Showing SARS-CoV-2 Antiviral Activity For Its HT-002 Candidate   Benzinga
Mar 22, 2021
08:40AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 22, 2021: ADBE, ENG, PCRX, RH, HOTH   Benzinga
08:01AM EDT  Hoth Therapeutics to Present at the Benzinga Biotech Small Cap Conference on   PR Newswire
Mar 19, 2021
07:00AM EDT  Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on   PR Newswire
Mar 18, 2021
07:10AM EDT  Iroquois Capital Management Reports 5.5% Stake in Hoth Therapeutics in 13G   Benzinga
Mar 17, 2021
02:21PM EDT  Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic   Benzinga
01:25PM EDT  Hoth Therapeutics Partners with University of Cincinnati to Perform Critical   PR Newswire
Mar 11, 2021
09:17AM EST  Hoth Executes Deal To Assess Effect Of HT-003 Therapeutic Platform On Ulcerative Colitis And Crohn's Disease   RTTNews
09:15AM EST  Hoth Therapeutics Reports Execution Of Deal To Assess Effect Of HT-003 Therapeutic Platform On Ulcerative Colitis, Crohn's Disease   Benzinga
09:15AM EST  Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic   PR Newswire
Mar 10, 2021
03:50PM EST  Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million   PR Newswire
Mar 9, 2021
09:17AM EST  The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data   Benzinga
Mar 8, 2021
05:01PM EST  Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market   PR Newswire
05:00PM EST  Hoth Therapeutics Reports 7.59M Share Common Stock Private Placement At $1.975/Share   Benzinga
Mar 3, 2021
08:03AM EST  Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002   PR Newswire
08:02AM EST  Hoth Therapeutics Offers Update On Its Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies: 1 Of 3 Peptide Candidates Has Demonstrated Low Level Viral Inhibition Assay With No Toxicity   Benzinga
Mar 1, 2021
03:02PM EST  Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human   PR Newswire
Feb 26, 2021
11:06AM EST  Hoth Therapeutics Reports Expansion Of License Deal To Include Innovative Cancer, Anaphylactic Treatment, No Terms Disclosed   Benzinga
11:05AM EST  Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and   PR Newswire
Feb 25, 2021
09:55AM EST  Hoth Therapeutics Retains RedChip to Increase Investor Awareness   PR Newswire
Feb 24, 2021
10:20AM EST  Hoth Therapeutics Says Expands Intellectual Property Portfolio With Novel Alzheimer's Treatment   Benzinga
10:20AM EST  Hoth Therapeutics Expands Intellectual Property Portfolio with Novel   PR Newswire
08:08AM EST  Hoth Therapeutics Filing Shows Co. Filed Provisional Patent Application With US Patent & Trademark Office For 'use of one of its current portfolio therapeutics to treat and prevent Alzheimer's disease'   Benzinga
Feb 23, 2021
08:17AM EST  Hoth Says Successfully Completed Pre-IND Meeting With FDA On Proposed Development Of HT-001 For Cancer Patients   RTTNews
08:04AM EST  Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA   PR Newswire
08:04AM EST  Hoth Therapeutics Reports Successful Completion Of Pre-Investigational New Drug Application Meeting With FDA Related To Proposed Development Of HT-001 For Cancer Patients   Benzinga
Feb 18, 2021
09:27AM EST  Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike   Benzinga
08:11AM EST  Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits   RTTNews
08:02AM EST  Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug   PR Newswire
08:02AM EST  Hoth Therapeutics reports Its HT-003 Showed Anti-Inflammatory Benefits, Co. Will Expand Drug Development To Include Treatment Of Inflammatory Bowel Diseases   Benzinga
Feb 17, 2021
08:02AM EST  Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth   PR Newswire
Feb 10, 2021
01:31PM EST  Hoth Therapeutics Highlights Publication Of Whitepaper Related To COVID-19 SARS-CoV-2 In bioRxiv   Benzinga
01:30PM EST  Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D.,   PR Newswire
Feb 9, 2021
08:05AM EST  Hoth Therapeutics Says Voltron Therapeutics Initiates Additional Animal Testing Of Self-Assembling COVID-19 Vaccine. BZ NOTE: Co And Voltron Are Developing HaloVax Together   Benzinga
08:00AM EST  Voltron Therapeutics, Inc. Initiates Additional Animal Testing of   GlobeNewswire Inc
Feb 8, 2021
02:53PM EST  Hoth Therapeutics Reports Partnership With Camargo Pharma Services For HT-001 Investigational New Drug Application For Treatment Of Cancer Patients   Benzinga
02:52PM EST  Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001   PR Newswire
Feb 2, 2021
08:48AM EST  Hoth Therapeutics Offers Update On Its Pipeline Of Novel Therapeutics Targeting Dermatological, COVID-19, Support Care Indications   Benzinga
08:45AM EST  Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline   PR Newswire
Jan 28, 2021
08:26AM EST  Hoth Expands Research Deal With Weill Cornell Medicine To Continue Advancement Of HT-003 For Acne Treatment   RTTNews
08:04AM EST  Hoth Therapeutics Extends Research Collaboration Agreement With Weill Cornell Medicine To Continue The Advancement Of HT-003 For Acne Treatment Research   Benzinga
08:03AM EST  Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell   PR Newswire
Jan 27, 2021
08:40AM EST  Hoth Therapeutics Adds Mario Lacouture To Scientific Advisory Board   RTTNews
08:31AM EST  Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board   PR Newswire
Jan 20, 2021
08:41AM EST  Hoth Announces Positive Initial Mechanism Of Action Data For HT-003 In Pursuit For Acne Treatment Indication   RTTNews
08:39AM EST  Hoth Therapeutics Initial Mechanism Of Action Data For HT-003 In Pursuit For Acne Treatment Indication   Benzinga
08:39AM EST  Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for   PR Newswire
Jan 19, 2021
04:28PM EST  Hoth Therapeutics Files Prospectus Relating To Sale Of Up To 3.713M Shares Of Common Stock Held By Selling Stockholders   Benzinga
Jan 13, 2021
04:30PM EST  Hoth Therapeutics 13G Filing From Intracoastal Capital Shows 7.6% Stake In Co.   Benzinga
12:21PM EST  Hoth Therapeutics shares were trading higher after the company reported the FDA granted a pre-IND meeting the regarding proposed drug development plan for HT-001 treatment for cancer patients.   Benzinga
08:44AM EST  Hoth Therapeutics Inc. (HOTH) said that the Pre-IND meeting requested last month for HT-001 with the U.S. Food and Drug Administration Division of Dermatology and Dental Products has been granted to receive written responses only from FDA that are targeted for delivery on February 22, 2021.   RTTNews
08:16AM EST  FDA Grants Hoth Pre-IND Meeting Regarding Proposed Drug Development Plan For HT-001 Treatment For Cancer Patients   RTTNews
08:03AM EST  FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug   PR Newswire
08:01AM EST  Hoth Reports FDA Granted Pre-Investigational New Drug Meeting Related To Cancer Patients Treatment   Benzinga
Jan 11, 2021
08:32AM EST  Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients   Benzinga
08:29AM EST  Hoth To Initiate IND Enabling Studies Of HT-001 Treatment For Cancer Patients   RTTNews
08:03AM EST  Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for   PR Newswire
Jan 5, 2021
09:07AM EST  Hoth Therapeutics Announces Private Placement Of Equity Priced At-The-Market; Agreement For $5.0 Mln In Gross Proceeds   RTTNews
09:02AM EST  Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market   PR Newswire
09:01AM EST  Hoth Therapeutics Reports $5M Private Placement Priced At The Market: ~2.48M Shares At $2.02/Share   Benzinga
Jan 4, 2021
08:57AM EST  Hoth Announces Licensing Deal With USAMRDC For Treating Multi-Drug Resistant Bacterial Lung Infections   RTTNews
08:04AM EST  Hoth Therapeutics Announces Licensing Agreement And Collaboration With U.S. Army Medical Research And Development Command For Treating Multi-Drug Resistant Bacterial Lung Infections   Benzinga
08:03AM EST  Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections   PR Newswire
Dec 31, 2020
10:09AM EST  Shares of Hoth Therapeutics, Inc. (HOTH) are surging over 50% on Wednesday after the biopharmaceutical company said it has signed a production deal for cancer treatment.   RTTNews
08:23AM EST  Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, said Thursday it has signed a production agreement with Tergus Pharma for both GLP and GMP materials associated with its novel cancer treatment drug, HT-001.   RTTNews
08:02AM EST  Hoth Therapeutics Signs Production Agreement For Both GLP And GMP Materials Associated With HT-001   RTTNews
08:01AM EST  Hoth Therapeutics Reports Signed Production Deal For Both GLP, GMP Materials Associated With HT-001 With Tergus Pharma For Its Novel Cancer Treatment Drug   Benzinga
08:01AM EST  Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment   PR Newswire
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 23, 2020
09:57AM EST  Hoth Therapeutics Submits Request For Pre-IND Meeting For HT-001, Treatment For Cancer Patients   RTTNews
09:56AM EST  Hoth Therapeutics Submits Request For A Pre-Investigational New Drug Meeting For HT-001 Treatment For Cancer Patients   Benzinga
09:55AM EST  Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND)   PR Newswire
Dec 21, 2020
08:52AM EST  Hoth Therapeutics Reports Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy In Cutaneous Lupus Erythematosus Mouse Model   Benzinga
08:31AM EST  Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in   PR Newswire
Dec 10, 2020
10:12AM EST  Hoth Therapeutics Receives Approval To Commence Phase 1b Clinical Trial of BioLexa For Treatment Of Atopic Dermatitis In Humans   Benzinga
10:11AM EST  Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of   PR Newswire
Nov 16, 2020
11:30AM EST  Voltron Therapeutics, Inc.today announced that it will participate in the 2020 FallTechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit. The conference will be held November 17-19, 2020.   GlobeNewswire Inc
Nov 5, 2020
09:49AM EST  6 Stocks Trading Near 52-Week Lows Just After Open On Thursday, Nov. 5, 2020: CORR, BMYr, WORX, CSCW, HOTH, TTNP   Benzinga
Nov 3, 2020
09:27AM EST  Hoth Reports Positive, Statistically Significant Proof-of-Concept Data On Therapeutic For Cutaneous Lupus Erythematosus   RTTNews
09:27AM EST  Hoth Therapeutics Announces Positive Statistically Significant Proof-Of-Concept Preclinical Data On Its Therapeutics For Cutaneous Lupus Erythematousus   Benzinga
09:25AM EST  Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease   PR Newswire
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Nov 2, 2020
10:17AM EST  Hoth Therapeutics Offers Update On Novel COVID-19 Therapeutic, Sees Key Proof-Of-Concept Data In Q4'20 Or Q1'21   Benzinga
10:16AM EST  Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go   PR Newswire
10:16AM EST  Hoth Therapeutics Offers Update On Novel COVID-19 Therapeutic, Sees Key Proof-Of-Concept Data In Q4'20   Benzinga
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 20, 2020
10:31AM EDT  Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA   PR Newswire
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Sep 24, 2020
08:40AM EDT  Hoth Therapeutics: HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2   RTTNews
08:39AM EDT  Hoth Therapeutics Announces HT-003 Initial Data In Inhibiting Toll-Like Receptor 2   Benzinga
08:38AM EDT  Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting   PR Newswire
Sep 21, 2020
10:06AM EDT  Hoth Therapeutics Enters Into Sponsored Research Deal For On-the-Go COVID-19 Testing Device   RTTNews
10:04AM EDT  Hoth Therapeutics Shares Spike Higher; Co Announces Entering Into Sponsored Research Agreement For On-The-Go Coronavirus Testing Device   Benzinga
10:03AM EDT  Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go   PR Newswire
Sep 16, 2020
09:42AM EDT  Voltron Therapeutics Reports Execution Of Manufacturing Deal With Global Contract Development, Manufacturing Organization For Its Hoth Therapeutics-Partnerd HaloVax COVID-19 Novel Vaccine Candidate   Benzinga
09:40AM EDT  Voltron Therapeutics, Inc. Executes Manufacturing Agreement with   GlobeNewswire Inc
Sep 15, 2020
08:31AM EDT  Voltron Therapeutics Announces Completion Of First Small Animal Safety And Immunogenicity Study Assessing The Effect Of Novel Coronavirus Vaccine, HaloVax   Benzinga
08:30AM EDT  Voltron Therapeutics, Inc. Announces Completion of First Small   GlobeNewswire Inc
Sep 11, 2020
08:13AM EDT  Hoth Therapeutics 8-K Shows Co. Entered Note Purchase Deal With Isoprene For $50K In Convertible Promissory Note Issued By Isoprene   Benzinga
Sep 1, 2020
08:03AM EDT  Hoth Therapeutics' Chief Scientific Officer, Dr. Stefanie Johns, to Appear on   PR Newswire
Aug 31, 2020
09:12AM EDT  Hoth Therapeutics Appoints Stefanie Johns As Chief Scientific Officer   Benzinga
09:10AM EDT  Hoth Therapeutics Appoints Stefanie Johns To The Position Of Chief Scientific Officer   RTTNews
09:08AM EDT  Hoth Therapeutics Appoints Stefanie Johns, Ph.D., as Chief Scientific Officer   PR Newswire
Aug 28, 2020
01:15PM EDT  Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in   PR Newswire
Aug 25, 2020
11:02AM EDT  Laidlaw Venture Partners Hosts Panel Discussion   GlobeNewswire Inc
Aug 19, 2020
09:11AM EDT  Hoth Therapeutics Updates On COVID-19 Initiatives And Dermatological Therapy Pipeline   RTTNews
09:09AM EDT  Hoth Therapeutics Provides Shareholder Update   Benzinga
09:08AM EDT  Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and   PR Newswire
Aug 13, 2020
09:12AM EDT  Hoth Therapeutics Reports Submitted Request To Australia Ethics Board To Begin Trial Of BioLexa For Atopic Dermatitis   Benzinga
09:10AM EDT  Hoth Therapeutic Submits Request To Australia Ethics Board To Begin Clinical Trial Of BioLexa For Atopic Dermatitis   RTTNews
09:08AM EDT  Hoth Therapeutic Announces That It Has Submitted its Request to Australia   PR Newswire
Aug 10, 2020
08:00AM EDT  Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device   Benzinga
07:58AM EDT  Hoth Therapeutics Licenses Intellectual Property to Develop Real-time,   PR Newswire
Jul 31, 2020
09:10AM EDT  Hoth Therapeutics Executes Licensing Agreement With Isoprene To Acquire Rights To VNLG-152   RTTNews
09:09AM EDT  Hoth Therapeutics Shares Spike Higher; Co. Executes Licensing Agreement Of VNLG-152 For Treatment Of Dermatological Diseases   Benzinga
09:08AM EDT  Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC